SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2000

OR

( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to _______________

Commission File Number 0-16211

DENTSPLY International Inc.
(Exact name of registrant as specified in its charter)

Delaware	39-1434669
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

570 West College Avenue, P. O. Box 872, York, PA	17405-0872
(Address of principal executive offices)	(Zip Code)

(717) 845-7511
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

(X) Yes ( ) No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: At May 5, 2000 the Company had 51,898,826 shares of Common Stock outstanding, with a par value of $.01 per share.

Exhibit Index at Page 17

DENTSPLY INTERNATIONAL INC.
FORM 10-Q

For Quarter Ended March 31, 2000

INDEX

PART I

FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

DENTSPLY INTERNATIONAL INC.

CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited)

	March 31, 2000	December 31, 1999
ASSETS		
Current assets:	(in thousands)	
Cash and cash equivalents	$ 7,298	$ 7,276
Accounts and notes receivable-trade, net	124,899	127,911
Inventories	136,497	135,480
Prepaid expenses and other current assets	38,875	44,001
Total Current Assets	307,569	314,668
Property, plant and equipment, net	177,461	180,536
Other noncurrent assets, net	14,828	14,963
Identifiable intangible assets, net	78,240	80,374
Costs in excess of fair value of net assets acquired, net	265,460	269,047
Total Assets	$ 843,558	$ 859,588
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	$ 37,203	$ 40,467
Accrued liabilities	80,089	80,922
Income taxes payable	41,247	34,676
Notes payable and current portion of long-term debt	18,163	20,155
Total Current Liabilities	176,702	176,220
Long-term debt	134,162	145,312
Deferred income taxes	20,789	20,240
Other liabilities	44,928	46,445
Total Liabilities	376,581	388,217
Minority interests in consolidated subsidiaries	2,426	2,499
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, $.01 par value; .25 million shares authorized; no shares issued		
Common stock, $.01 par value; 100 million shares authorized; 54.3 million shares issued at March 31, 2000 and 54.3 million shares issued shares issued at December 31, 1999	543	543
Capital in excess of par value	151,479	151,509
Retained earnings	421,349	402,408
Accumulated other comprehensive income (loss)	(47,483)	(43,209)
Employee stock ownership plan reserve	(6,078)	(6,458)
Treasury stock, at cost, 2.3 million shares at March 31, 2000 and 1.5 million shares at December 31, 1999	(55,259)	(35,921)
Total Stockholders' Equity	464,551	468,872
Total Liabilities and Stockholders' Equity	$ 843,558	$ 859,588

See accompanying notes to unaudited consolidated condensed financial statements.

DENTSPLY INTERNATIONAL INC.
CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(unaudited)

	Three Months Ended March 31, 2000	Three Months Ended March 31, 1999
	(in thousands, except per share data)	
Net sales	$212,530	$196,589
Cost of products sold	102,013	94,960
Gross profit	110,517	101,629
Selling, general and administrative expenses	73,777	67,320
Operating income	36,740	34,309
Interest expense	3,000	4,573
Interest income	(389)	(121)
Other (income) expense, net	23	(554)
Income before income taxes	34,106	30,411
Provision for income taxes	11,913	10,884
Net income	$ 22,193	$19,527
Earnings per common share:		
Basic	$.42	$.37
Diluted	$.42	$.37
Cash dividends declared per common share	$.0625	$.05625
Weighted average common shares outstanding:		
Basic	52,315	52,566
Diluted	52,536	52,758

See accompanying notes to unaudited consolidated condensed financial statements.

DENTSPLY INTERNATIONAL INC.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(unaudited)

	Three Months Ended March 31,	
	2000	1999
	(in thousands)	
Cash flows from operating activities:		
Net income	$ 22,193	$ 19,527
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	5,925	5,090
Amortization	4,811	5,519
Other, net	7,783	(12,885)
Net cash provided by operating activities	40,712	17,251
Cash flows from investing activities:		
Acquisition of businesses, net of cash acquired	---	3,446
Property, plant and equipment additions	(7,018)	(6,668)
Other, net	(528)	---
Net cash used in investing activities	(7,546)	(3,222)
Cash flows from financing activities:		
Debt repayment	(86,787)	(27,574)
Proceeds from long-term debt	75,907	7,653
Increase in bank overdrafts and other short-term borrowings	(1,506)	12,829
Cash paid for treasury stock	(19,973)	---
Cash dividends paid	(3,295)	(5,912)
Other, net	985	1,837
Net cash used in financing activities	(34,669)	(11,167)
Effect of exchange rate changes on cash and cash equivalents	1,525	(2,444)
Net increase in cash and cash equivalents	22	418
Cash and cash equivalents at beginning of period	7,276	8,690
Cash and cash equivalents at end of period	$ 7,298	$ 9,108
Supplemental disclosures of cash flow information:		
Interest paid	$ 2,351	$ 3,848
Income taxes paid	4,528	6,662

See accompanying notes to unaudited consolidated condensed financial statements.

DENTSPLY INTERNATIONAL INC.
CONSOLIDATED CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY
(unaudited)

(in thousands)	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Income(Loss)	ESOP Reserve	Treasury Stock	Total Stockholders' Equity
Balance at December 31, 1999	$ 543	$151,509	$402,408	$(43,209)	$ (6,458)	$(35,921)	$468,872
Comprehensive Income:							
Net income			22,193				22,193
Other comprehensive income							
Foreign currency translation adjustments				(4,274)			(4,274)
Comprehensive Income							17,919
Exercise of stock options and warrants		(81)				635	554
Tax benefit related to stock options and warrants exercised		51					51
Repurchase of .81 million shares of common stock						(19,973)	(19,973)
Cash dividends declared, $.0625 per share			(3,252)				(3,252)
Net change in ESOP reserve					380		380
Balance at March 31, 2000	$ 543	$151,479	$421,349	$(47,483)	$ (6,078)	$(55,259)	$464,551

See accompanying notes to unaudited consolidated condensed financial statements.

DENTSPLY INTERNATIONAL INC.

NOTES TO UNAUDITED INTERIM CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2000

The accompanying unaudited interim consolidated condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) which in the opinion of management are necessary for a fair presentation of financial position, results of operations and cash flows for the interim periods. These interim financial statements conform to the requirements for interim financial statements and consequently do not include all the disclosures normally required by generally accepted accounting principles. Disclosures included in the Company's most recent 10-K Filed March 30, 2000 are updated where appropriate.

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The consolidated condensed financial statements include the accounts of DENTSPLY International Inc. (the "Company") and its subsidiaries. Minority interests in net income of consolidated subsidiaries are not material and are included in other (income) expense, net.

Inventories

Inventories are stated at the lower of cost or market. At March 31, 2000 and December 31, 1999, the cost of $14.4 million or 11% and $15.5 million or 11%, respectively, of inventories was determined by the last-in, first-out (LIFO) method. The cost of other inventories was determined by the first-in, first-out (FIFO) or average cost method.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, net of accumulated depreciation. Except for leasehold improvements, depreciation for financial reporting purposes is computed by the straight-line method over the following estimated useful lives: buildings - generally 40 years; and machinery and equipment - 4 to 15 years. The cost of leasehold improvements is amortized over the shorter of the estimated useful life or the term of the lease. For income tax purposes, depreciation is computed using various methods.

Derivatives

The Company's only involvement with derivative financial instruments is forward contracts to hedge certain assets and liabilities denominated in foreign currencies and swap agreements which convert current floating interest debt to fixed rates.

NOTE 2 - EARNINGS PER COMMON SHARE

The following table sets forth the computation of basic and diluted earnings per common share:

	Three Months Ended March 31, 2000	Three Months Ended March 31, 1999
Basic EPS Computation:		
Numerator(Income)	$22,193	$19,527
Denominator:		
Common shares outstanding	52,315	52,566
Basic EPS	$ .42	$ .37
Diluted EPS Computation:		
Numerator(Income)	$22,193	$19,527
Denominator:		
Common shares outstanding	52,315	52,566
Incremental shares from assumed exercise of dilutive options and warrants	221	192
Total shares	52,536	52,758
Diluted EPS	$ .42	$ .37

NOTE 3 - INVENTORIES

Inventories consist of the following:

	March 31, 2000	December 31, 1999
	(in thousands)	
Finished goods	$ 81,304	$ 77,786
Work-in-process	23,599	25,519
Raw materials and supplies	31,594	32,175
	$136,497	$135,480

Pre-tax income was $.1 million lower in the three months ended March 31, 2000 and $.1 million lower for the same period in 1999 as a result of using the LIFO method compared to the first-in, first-out (FIFO) method. If the FIFO method had been used to determine the cost of the LIFO inventories, the amounts at which net inventories are stated would be lower than reported at March 31, 2000 and December 31, 1999 by $.2 million and $.3 million, respectively.

NOTE 4 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consist of the following:

	March 31, 2000	December 31, 1999
	(in thousands)	
Assets, at cost:		
Land	$ 14,762	$ 15,405
Buildings and improvements	84,939	86,148
Machinery and equipment	159,042	155,735
Construction in progress	9,972	9,836
	268,715	267,124
Less: Accumulated depreciation	91,254	86,588
	$177,461	$180,536

NOTE 5 - NOTES PAYABLE AND LONG-TERM DEBT

The decreases from December 31, 1999 in notes payable and current portion of long-term debt ($2.0 million)and long-term debt ($11.2 million) were primarily due to the company's strong cash flows from operating activities.

NOTE 6 - RESTRUCTURING AND OTHER COSTS

In 1998, the Company recorded restructuring charges related to the closure of its German tooth manufacturing facility and the discontinuance of its New Image division's intra-oral camera business. The activity related to these restructurings was disclosed in the Company's most recent 10-K filed March 30, 2000 (Note 15). There was no material activity related to these restructurings during the period ended March 31, 2000.

NOTE 7 - COMMITMENTS AND CONTINGENCIES

DENTSPLY and its subsidiaries are from time to time parties to lawsuits arising out of their respective operations. The Company believes that pending litigation to which DENTSPLY is a party will not have a material adverse effect upon its consolidated financial position or results of operations.

In June 1995, the Antitrust Division of the United States Department of Justice initiated an antitrust investigation regarding the policies and conduct undertaken by the Company's Trubyte Division with respect to the distribution of artificial teeth and related products. On January 5, 1999 the Department of Justice filed a complaint against the Company in the U.S. District Court in Wilmington, Delaware alleging that the Company's tooth distribution practices violate the antitrust laws and seeking an order for the Company to discontinue its practices. Three follow on private class action suits on behalf of dentists, laboratories and denture patients in seventeen states, respectively, who purchased Trubyte teeth or products containing Trubyte teeth were filed and transferred to the U.S. District Court in Wilmington, Delaware. These cases have been assigned to the same judge who is handling the Department of Justice action. The class action filed on behalf of the dentists has been dismissed by the plaintiffs. The private party suits seek damages in an unspecified amount. The Company has filed a motion for summary judgment in the Department of Justice case. It is the Company's position that the conduct and activities of the Trubyte Division do not violate the antitrust laws.

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations

Certain statements made by the Company, including without limitation, statements containing the words "plans", "anticipates", "believes", "expects", or words of similar import constitute forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may materially affect the Company's business and prospects, and should be read in conjunction with the risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 1999.

RESULTS OF OPERATIONS

Quarter Ended March 31, 2000 Compared to Quarter Ended March 31, 1999

For the quarter ended March 31, 2000, net sales increased $15.9 million, or 8.1%, to $212.5 million, up from $196.6 million in the same period of 1999.

Base business sales grew 11.1% in the first quarter. The impact of currency translation had a significant negative effect of 3.0% on the first quarter results compared to the comparable period in 1999 due to the strengthening of the U.S. dollar against the major European currencies.

Sales for the first quarter in the United States grew 12.6%. Base business growth in ultrasonic and x-ray equipment, consumables and other dental products was partially offset by sales declines in handpieces and non-dental products.

European base business sales, including the Commonwealth of Independent States (CIS), increased 4.6%. This, however, was offset by the impact of currency translation, which had a negative 10.2% effect on the quarter. Sales of consumables in Germany rebounded compared to the prior year quarter but was partially offset by weak sales of equipment.

Asia (excluding Japan) and Latin America sales increased 28.8% as the 30.7% increase in base business sales was offset slightly by the impact of currency translation, which had a negative 1.9% on the quarter. Asia's base business grew 80.8% as the Asian economy continued to stabilize. Prior year Asian sales were impacted by returns from over extended dealers in India. The Asian base business sales increase would have been 30.9% without the increase from India's sales. Base business in Latin America grew 15.8% in local currency, including some large intermittent government and dental school sales, offset by a decline of 2.9% due to currency translation. Due to the infrequency of these government and school sales, the growth rate in the first quarter is not expected to be sustained.

Sales in the rest of the world grew 6.8%: 5.3% from base business primarily in Canada and Middle East/Africa (MEA); plus 1.5% from the impact of currency translation.

Consumable product sales were up 9.6% including base business sales growth of 12.8%, less 3.2% from the impact of currency translation.

Equipment base sales increased 8.7%. Dental x-ray equipment base sales increased 6.8% and ultrasonic base business sales increased 18.3% (up 10% without the increase from India). These increases were offset somewhat by negative 2.6% from currency translation and a slight reduction in the sale of handpieces.

Gross profit grew 8.7% in the first quarter due to higher sales and a higher gross profit percentage. The 2000 first quarter gross profit percentage was 52.0% compared to 51.7% for the first quarter of 1999. This resulted from favorable product mix and operating improvements, offset partially by the negative impacts of exchange rates.

Selling, general and administrative (SG&A) expenses increased $6.5 million, or 9.6%. As a percentage of sales, expenses increased from 34.2% in the first quarter of 1999 to 34.7% for the same period of 2000. This increase was mainly due to sales and marketing expenses associated with new product launches as well as expenses related to the introduction of PepGen P-15 (new product for the treatment of osseous or "bony" defects resulting from moderate to severe periodontitis) to the periodontal community. In addition, the first quarter of 1999 included a credit of $1.1 million for pension expense in Germany resulting from the curtailment of the Dreieich operation pension plan.

Net interest expense decreased $1.8 million in the first quarter of 2000 due to lower debt in 2000 and savings in interest expense resulting from lower rate Swiss debt. Other income decreased $.6 million in the first quarter of 2000. Other income in the first quarter of 1999 included $.8 million related to the divestiture of medical businesses in 1994.

Income before income taxes increased $3.7 million, or 12.2% to $34.1 million from $30.4 million in the first quarter of 1999. The effective tax rate for operations was lowered to 34.9% in the first quarter of 2000 compared to 35.8% in the first quarter of 1999 reflecting savings from federal, state and foreign tax planning activities. Net income increased $2.7 million, or 13.7%, from the first quarter of 1999 due to higher sales, higher gross profit as a percentage of net sales, lower net interest expense, and a lower provision for income tax. Basic and diluted earnings per common share increased from $.37 in 1999 to $.42 in 2000, or 13.5%.

LIQUIDITY AND CAPITAL RESOURCES

Investing activities for the three months ended March 31, 2000 include capital expenditures of $7.0 million.

In December 1999, the Board of Directors authorized a stock buyback program for 2000 to purchase up to 1.0 million shares of common stock on the open market or in negotiated transactions. In March 2000, the Board of Directors made an amendment to this program which increased the number of shares to 4.0 million. During the first three months of 2000, the Company repurchased .8 million shares of its common stock for approximately $20 million. The timing and amounts of any additional purchases will depend upon many factors, including market conditions and the Company's business and financial condition.

The Company's current ratio was 1.7 with working capital of $130.7 million at March 31, 2000. This compares with a current ratio of 1.8 and working capital of $138.4 million at December 31, 1999.

At the beginning of the first quarter, the Company converted approximately $60 million under its revolving credit agreement to Swiss francs. This enabled the Company to not only reduce its interest expense by 2.5% to 3.5% but also allowed the Company to naturally hedge its Swiss franc exposure on its investments in Switzerland. The Company expects on an ongoing basis, to be able to finance cash requirements, including capital expenditures, stock repurchases, debt service, and possible future acquisitions, from the funds generated from operations and amounts available under the existing Bank Revolving Loan and Commercial Paper facilities.

For the three months ended March 31, 2000, cash flows from operating activities were $40.7 million compared to $17.3 million for the three months ended March 31, 1999. The 1999 cash flows from operating activities included $9.2 million of negative cash flows associated with the two restructurings recorded in 1998. The increase of $23.4 million results primarily from increased earnings, decreases in accounts receivable, deferred income taxes and prepaid expenses and other current assets and increases in accrued liabilities offset by increases in inventories.

NEW STANDARDS

Statement of Financial Accounting Standards No. 133 ("FASB 133"), "Accounting for Derivative Instruments and Hedging Activities," was issued by the Financial Accounting Standards Board (FASB) in June 1998. This Statement establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities. It requires recognition of all derivatives as either assets or liabilities on the balance sheet and measurement of those instruments at fair value. If certain conditions are met, a derivative may be designated specifically as (a) a hedge of the exposure to changes in the fair value of a recognized asset or liability or an unrecognized firm commitment referred to as a fair value hedge, (b) a hedge of the exposure to variability in cash flows of a forecasted transaction (a cash flow hedge), or (c) a hedge of the foreign currency exposure of a net investment in a foreign operation, an unrecognized firm commitment, an available-for-sale security, or a forecasted transaction.

This statement was originally required to be adopted effective January 1, 2000; however, in June 1999 FASB issued SFAS No. 137 "Accounting for Derivative Instruments and Hedging Activities - Deferral of the Effective Date of FASB Statement No. 133", which delays the effective date to January 1, 2001. The Company has not yet determined the full effect of adopting FASB 133.

YEAR 2000

The changeover to the year 2000 ("Y2K") has resulted in no significant issues or problems for the Company. Worldwide operations continued without interruption as the Company's information systems, equipment and utility providers functioned as normal throughout the transition. In addition, to date, the Company has not been adversely impacted by any Y2K problems experienced by its customers or vendors. Although the Company has not experienced any Y2K problems, it is continuing to monitor potential areas of risk.

EURO CURRENCY CONVERSION

On January 1, 1999, eleven of the fifteen member countries of the European Union (the "participating countries") established fixed conversion rates between their legacy currencies and the newly established Euro currency.

The legacy currencies will remain legal tender in the participating countries between January 1, 1999 and January 1, 2002 (the "transition period"). Starting January 1, 2002 the European Central Bank will issue Euro-denominated bills and coins for use in cash transactions. On or before July 1, 2002, the legacy currencies of participating countries will no longer be legal tender for any transactions.

The Company's various operating units which are affected by the Euro conversion intend to keep their books in their respective legacy currency through a portion of the three year transition period. At this time, the Company does not expect the reasonable foreseeable consequences of the Euro conversion to have material adverse effects on the Company's business, operations or financial condition.

IMPACT OF INFLATION

The Company has generally offset the impact of inflation on wages and the cost of purchased materials by reducing operating costs and increasing selling prices to the extent permitted by market conditions.

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

There have been no significant material changes to the market risks as disclosed in the Company's Annual Report on Form 10-K filed for the year ending December 31, 1999.

PART II
OTHER INFORMATION

Item 1 - Legal Proceedings

DENTSPLY and its subsidiaries are from time to time parties to lawsuits arising out of their respective operations. The Company believes that pending litigation to which DENTSPLY is a party will not have a material adverse effect upon its consolidated financial position or results of operations.

In June 1995, the Antitrust Division of the United States Department of Justice initiated an antitrust investigation regarding the policies and conduct undertaken by the Company's Trubyte Division with respect to the distribution of artificial teeth and related products. On January 5, 1999 the Department of Justice filed a complaint against the Company in the U.S. District Court in Wilmington, Delaware alleging that the Company's tooth distribution practices violate the antitrust laws and seeking an order for the Company to discontinue its practices. Three follow on private class action suits on behalf of dentists, laboratories and denture patients in seventeen states, respectively, who purchased Trubyte teeth or products containing Trubyte teeth were filed and transferred to the U.S. District Court in Wilmington, Delaware. These cases have been assigned to the same judge who is handling the Department of Justice action. The class action filed on behalf of the dentists has been dismissed by the plaintiffs. The private party suits seek damages in an unspecified amount. The Company has filed a motion for summary judgment in the Department of Justice case. It is the Company's position that the conduct and activities of the Trubyte Division do not violate the antitrust laws.

Item 6 - Exhibits and Reports on Form 8-K

(a) Exhibits. The following exhibits are filed herewith:

Number	Description
27	Financial Data Schedule (pursuant to Item 601(c)(1)(iv) of Regulation S-K, this exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended)

(b) Reports on Form 8-K

On February 16, 2000 the Company filed a Form 8-K, under item 4, reporting that it had changed its Certifying Accountants effective for the 2000 fiscal year and other information required by Regulation S-K Item 304. On March 1, 2000, Amendment 1 to this Form 8-K was filed on Form 8-K/A, under items 4 and 7. This amendment related to the inclusion of a letter from the former accountants stating whether they agree or disagree with the statements made by the Company under item 4.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DENTSPLY INTERNATIONAL INC.

May 15, 2000	/s/	John C. Miles II
Date		John C. Miles II Chairman and Chief Executive Officer
May 15, 2000	/s/	William R. Jellison
Date		William R. Jellison Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Number	Description	Sequential Page No.
27	Financial Data Schedule (pursuant to Item 601(c)(1)(iv) of Regulation S-K, this exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended)	18

THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS OF DENTSPLY INTERNATIONAL INC. AT MARCH 31, 2000 AND FOR THE FISCAL QUARTER THEN ENDED, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.

0000818479
DENTSPLY INTERNATIONAL
1000

3-MOS
DEC-31-2000
JAN-01-2000
MAR-31-2000
7298
0
124899
0
136497
307569
268715
91254
843558
176702
134162
0
0
543
464008
843558
212530
212530
102013
102013
73777
0
3000
34106
11913
22193
0
0
0
22193
0.42
0.42